Lloyd Segal

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.

Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada.

Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Pembroke American Growth Fund, Inc. is an open-end investment fund. The company distributes earnings to unit holders as income, dividends or capital gains. It holds interest in pursing long-term growth through capital appreciation by investing in smaller U.S. companies to have above-average growth potential or to be undervalued. The company was founded on October 1, 1988 and is headquartered in Montreal, Canada.